Luminal A Breast Cancer and Molecular Assays: A Review

Overview

Journal Oncologist

Publisher Oxford University Press

Specialty Oncology

Date 2018 Feb 24

PMID 29472313

Citations 88

Authors

Jennifer J Gao

Sandra M Swain

Affiliations

Soon will be listed here.

Abstract

Purpose: Chemotherapy has been the historical mainstay of treatment for patients with breast cancer, with immunohistochemical markers and tumor characteristics driving treatment decisions. The discovery of different intrinsic subtypes of breast cancer has advanced the understanding of breast cancer, with gene-based assays shedding further light on tumor behavior and response to treatment.

Design: This review focuses on the landscape of the luminal A subtype, its definition based on immunohistochemistry (IHC) and gene assays, the prognostic and predictive value of these assays, guideline recommendations, and treatment implications.

Results: Clinical studies of the prognostic value of gene-based and IHC-based assays in patients with luminal A-subtype breast cancers suggest a better prognosis for these patients compared with those with breast cancers of other subtypes.

Conclusion: In today's era of precision medicine, the best treatment regimen for patients with luminal A-subtype tumors is still undetermined, but available data raise the question whether chemotherapy can be omitted and endocrine therapy alone is sufficient for this patient population.

Implications For Practice: Immunohistochemical markers have traditionally guided treatment decisions in breast cancer. However, advances in gene-expression profiling and availability of gene-based assays have launched these newer tests into everyday clinical practice. Luminal A-subtype tumors are a unique subset that may have favorable tumor biology. Properly defining this tumor subtype is important and may identify a subset of patients for whom endocrine therapy alone is sufficient.

Citing Articles

Emerging importance of HER3 in tumorigenesis and cancer therapy.

Garrett J, Tendler S, Feroz W, Kilroy M, Yu H Nat Rev Clin Oncol. 2025; .

PMID: 40087402 DOI: 10.1038/s41571-025-01008-y.

Real-World Quality-of-Life Data in Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors Using Four Assessment Tools.

Stanciu I, Nitipir C Cancers (Basel). 2025; 17(5).

PMID: 40075666 PMC: 11899285. DOI: 10.3390/cancers17050818.

miRNAs as emerging predictors of tamoxifen resistance in breast cancer.

Beilankouhi E, Safaralizadeh R, Nejati B, Sanaat Z, Gharamaleki J, Esfahani A Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40042561 DOI: 10.1007/s00210-025-03936-z.

The Breast Cancer Classifier refines molecular breast cancer classification to delineate the HER2-low subtype.

Turova P, Kushnarev V, Baranov O, Butusova A, Menshikova S, Yong S NPJ Breast Cancer. 2025; 11(1):19.

PMID: 39979291 PMC: 11842814. DOI: 10.1038/s41523-025-00723-0.

Advances in Ultrasound-Targeted Microbubble Destruction (UTMD) for Breast Cancer Therapy.

Wu Y, Liu Y, Wu H, Tong M, Du L, Ren S Int J Nanomedicine. 2025; 20:1425-1442.

PMID: 39925678 PMC: 11804227. DOI: 10.2147/IJN.S504363.

References

Gluck S, de Snoo F, Peeters J, Stork-Sloots L, Somlo G . Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy. Breast Cancer Res Treat. 2013; 139(3):759-67. DOI: 10.1007/s10549-013-2572-4. View

Santarpia L, Bottai G, Kelly C, Gyorffy B, Szekely B, Pusztai L . Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer. Oncologist. 2016; 21(9):1063-78. PMC: 5016060. DOI: 10.1634/theoncologist.2015-0369. View

Jatoi I, Anderson W, Jeong J, Redmond C . Breast cancer adjuvant therapy: time to consider its time-dependent effects. J Clin Oncol. 2011; 29(17):2301-4. PMC: 3107746. DOI: 10.1200/JCO.2010.32.3550. View

Klein M, Dabbs D, Shuai Y, Brufsky A, Jankowitz R, Puhalla S . Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis. Mod Pathol. 2013; 26(5):658-64. PMC: 3647116. DOI: 10.1038/modpathol.2013.36. View

Peto R, Davies C, Godwin J, Gray R, Pan H, Clarke M . Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2011; 379(9814):432-44. PMC: 3273723. DOI: 10.1016/S0140-6736(11)61625-5. View

Krijgsman O, Roepman P, Zwart W, Carroll J, Tian S, de Snoo F . A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response. Breast Cancer Res Treat. 2011; 133(1):37-47. DOI: 10.1007/s10549-011-1683-z. View

Esserman L, Yau C, Thompson C, J van t Veer L, Borowsky A, Hoadley K . Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades. JAMA Oncol. 2017; 3(11):1503-1510. PMC: 5710197. DOI: 10.1001/jamaoncol.2017.1261. View

Kittaneh M, Montero A, Gluck S . Molecular profiling for breast cancer: a comprehensive review. Biomark Cancer. 2013; 5:61-70. PMC: 3825646. DOI: 10.4137/BIC.S9455. View

Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier A, Cowens J . Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol. 2013; 31(22):2783-90. DOI: 10.1200/JCO.2012.46.1558. View

10.

Anderson W, Rosenberg P, Katki H . Tracking and evaluating molecular tumor markers with cancer registry data: HER2 and breast cancer. J Natl Cancer Inst. 2014; 106(5). PMC: 4677264. DOI: 10.1093/jnci/dju093. View

11.

Kroemer G, Senovilla L, Galluzzi L, Andre F, Zitvogel L . Natural and therapy-induced immunosurveillance in breast cancer. Nat Med. 2015; 21(10):1128-38. DOI: 10.1038/nm.3944. View

12.

Parker J, Mullins M, Cheang M, Leung S, Voduc D, Vickery T . Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009; 27(8):1160-7. PMC: 2667820. DOI: 10.1200/JCO.2008.18.1370. View

13.

Maisonneuve P, Disalvatore D, Rotmensz N, Curigliano G, Colleoni M, Dellapasqua S . Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes. Breast Cancer Res. 2014; 16(3):R65. PMC: 4095689. DOI: 10.1186/bcr3679. View

14.

Buyse M, Loi S, Veer L, Viale G, Delorenzi M, Glas A . Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst. 2006; 98(17):1183-92. DOI: 10.1093/jnci/djj329. View

15.

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

16.

Dowsett M, Cuzick J, Wale C, Forbes J, Mallon E, Salter J . Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010; 28(11):1829-34. DOI: 10.1200/JCO.2009.24.4798. View

17.

J van t Veer L, Dai H, van de Vijver M, He Y, Hart A, Mao M . Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415(6871):530-6. DOI: 10.1038/415530a. View

18.

Rocca A, Farolfi A, Maltoni R, Carretta E, Melegari E, Ferrario C . Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer. Breast Cancer Res Treat. 2015; 152(1):57-65. DOI: 10.1007/s10549-015-3423-2. View

19.

Curigliano G, Burstein H, Winer E, Gnant M, Dubsky P, Loibl S . De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017; 28(8):1700-1712. PMC: 6246241. DOI: 10.1093/annonc/mdx308. View

20.

Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z . Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy.... Ann Oncol. 2013; 25(2):339-45. DOI: 10.1093/annonc/mdt494. View